Literature DB >> 34261448

Incidence and risk factors of post-operative cognitive decline after ablation for atrial fibrillation.

Jing Zhang1,2, Shi-Jun Xia1, Xin Du1, Chao Jiang1, Yi-Wei Lai1, Yu-Feng Wang1, Zhao-Xu Jia1, Liu He1, Ri-Bo Tang1, Jian-Zeng Dong1, Chang-Sheng Ma3.   

Abstract

BACKGROUND: Catheter ablation is widely used in atrial fibrillation (AF) management. In this study, we are aimed to investigate the incidence of postprocedural cognitive decline in a larger population undergoing AF ablation under local anesthesia, and to evaluate the associated risk factors.
METHODS: This study included 287 patients with normal cognitive functions, with 190 ablated AF patients (study group) and 97 AF patients who are awaiting ablation (practice group). We assessed the neuropsychological function of each patient for twice (study group: 24 h prior to ablation and 48 h post ablation; practice group: on the day of inclusion and 72 h later but before ablation). The reliable change index was used to analyze the neuropsychological testing scores and to identify postoperative cognitive dysfunction (POCD) at 48 h post procedure. Patients in the study group accepting a 6-month follow up were given an extra cognitive assessment.
RESULTS: Among the ablated AF patients, 13.7% (26/190) had POCD at 48 h after the ablation procedure. Multivariable analysis revealed that, a minimum intraoperative activated clotting time (ACT) < 300 s (OR 3.82, 95% CI 1.48-9.96, P = 0.006) and not taking oral anticoagulants within one month prior to ablation(OR 10.35, 95% CI 3.54-30.27, P < 0.001) were significantly related to POCD at 48 h post-ablation. In 172 patients of the study group accepting a 6-month follow up, there were 23 patients with POCD at 48 h post-ablation and 149 patients without POCD. The global cognitive scores were decreased in 48 h post-operation tests (0 ± 1 vs - 0.15 ± 1.10, P < 0.001) and improved significantly at 6 months post-operation (0 ± 1 vs 0.43 ± 0.92, P < 0.001). In the 23 patients with POCD at 48 h after the procedure, global cognitive performance at 6 months was not significantly different compared with that at baseline (- 0.05 ± 1.25 vs - 0.19 ± 1.33, P = 0.32), while 13 of them had higher scores than baseline level.
CONCLUSIONS: Incident of POCD after ablation procedures is high in the short term. Inadequate periprocedural anticoagulation are possible risk factors. However, most POCD are reversible at 6 months, and a general improvement was observed in cognitive function at 6 months after ablation.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34261448     DOI: 10.1186/s12872-021-02139-7

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


  1 in total

1.  Pulmonary vein antral isolation for paroxysmal atrial fibrillation: results from long-term follow-up.

Authors:  C Medi; P B Sparks; J B Morton; P M Kistler; K Halloran; R Rosso; J K Vohra; S Kumar; J M Kalman
Journal:  J Cardiovasc Electrophysiol       Date:  2010-08-31
  1 in total
  3 in total

Review 1.  Association of Catheter Ablation and Reduced Incidence of Dementia among Patients with Atrial Fibrillation during Long-Term Follow-Up: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Andrea Saglietto; Andrea Ballatore; Henri Xhakupi; Gaetano Maria De Ferrari; Matteo Anselmino
Journal:  J Cardiovasc Dev Dis       Date:  2022-04-30

2.  Catheter ablation and cognitive function in atrial fibrillation: A systematic review and meta-analysis.

Authors:  Pengfei Chen; Zhuhong Chen; Deng Pan; Lina Miao; Yujiao Shi; Ming Guo; Jianpeng Du
Journal:  Front Neurol       Date:  2022-09-08       Impact factor: 4.086

Review 3.  Impact of catheter ablation versus medical therapy on cognitive function in atrial fibrillation: a systematic review.

Authors:  Neil Bodagh; Reuben Yap; Irum Kotadia; Iain Sim; Ajay Bhalla; Peter Somerville; Mark O'Neill; Steven E Williams
Journal:  J Interv Card Electrophysiol       Date:  2022-04-05       Impact factor: 1.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.